News

QRxPharma has initiated a phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo IV (intravenous morphine and oxycodone) versus IV morphine alone. It is

Promedior has initiated phase 1 clinical trial of PRM-151, a novel compound in development for the treatment of fibrotic diseases and tissue remodeling. The phase 1 dose escalation

Seattle Genetics has reported revenues in the second quarter of 2009 as $9.4 million, compared to $10 million in the second quarter of 2008. For the first six

The Siemens booth at this year’s 2009 AACC will feature a number of Siemens newest instruments and assays, including: Dimension EXL with LM (LOCI module) System Dimension Vista

Affymetrix, a developer of products that accelerate genetic research, has posted its operating results that revealed a negative impact for the second quarter of 2009. The company’s total

Anika Therapeutics has reported that total revenue for the second quarter of 2009 showed an increase of 5%, to $9.52 million, from $9.06 million in the second quarter

Human Genome (HGSI) has received second purchase order from the US government as an additional 45,000 doses of raxibacumab (ABthrax), for the Strategic National Stockpile, to be delivered

NewBridge has entered into a license and supply agreement with Axcan for Pylera, a patented 3-in-1 capsule therapy for the eradication of Helicobacter pylori. Each Pylera capsule contains

Response Genetics has entered into a purchase agreement with certain funds managed by Lansdowne Partners Limited Partnership, to raise approximately $4 million. The company is likely to raise